Tag: NASDAQ: DMPI
April 30, 2018
8 Glioblastoma Treatment Stocks
With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...
April 10, 2018
Investing in Glioblastoma Treatments
Glioblastoma tumors are one of the most aggressive forms of cancer and yet have very few treatments. Here's how investing...
December 26, 2017
DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new... November 21, 2017
DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting
DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today provided... November 14, 2017
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results
DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) has announced financial results for Q1 ended September 30, 2017. The Company also announced a business... November 7, 2017
DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer
DelMar Pharmaceuticals, Inc. (Nasdaq:DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today... October 31, 2017
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer
DelMar Pharmaceuticals, Inc. (Nasdaq:DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today... October 10, 2017
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public... October 3, 2017
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a... September 29, 2017